RUBY - Rubius Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
13.97
-0.59 (-4.05%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close14.56
Open14.50
Bid11.19 x 900
Ask20.00 x 800
Day's Range12.71 - 14.65
52 Week Range4.10 - 33.01
Volume285,862
Avg. Volume181,549
Market Cap1.104B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.60
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.75
Trade prices are not sourced from all markets
  • GlobeNewswire13 days ago

    Rubius Therapeutics Highlights Upcoming 2019 Milestones at the 37th Annual J.P. Morgan Healthcare Conference

    Rubius Therapeutics, Inc. (RUBY), a biotechnology company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, today announced anticipated 2019 development milestones. Pablo J. Cagnoni, M.D., chief executive officer, will present these updates and review 2018 accomplishments today at 9:00 a.m. PT at the 37th Annual J.P. Morgan Healthcare Conference. “At Rubius Therapeutics, we made tremendous progress in 2018, transforming from a privately-held company into a publicly-traded, fully integrated research and development organization that is advancing a robust pipeline of Red Cell Therapeutics™ for the potential treatment of rare enzyme deficiencies, cancer and autoimmune diseases,” said Dr. Cagnoni.

  • GlobeNewswire24 days ago

    Rubius Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Dec. 27, 2018 -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biotechnology company developing an entirely new class of allogeneic cellular therapies,.

  • GlobeNewswirelast month

    Rubius Therapeutics, Inc. Secures $75 Million Loan Facility

    Rubius Therapeutics, Inc. (RUBY), a biotechnology company developing an entirely new class of allogeneic cellular therapies, today announced it has entered into a loan and security agreement with Solar Capital Partners and its affiliates for a term loan of up to $75.0 million to be funded in three tranches of $25.0 million each. The proceeds will be used to advance its pipeline of Red Cell Therapeutics™ and for general corporate purposes, further extending the Company’s cash runway into 2021. “This flexible, non-dilutive financing strengthens our financial position and supports our key therapeutic programs advancing towards clinical trials,” said Pablo J. Cagnoni, M.D., chief executive officer of Rubius Therapeutics.

  • GlobeNewswirelast month

    Rubius Therapeutics Added to Nasdaq Biotechnology Index

    CAMBRIDGE, Mass., Dec. 17, 2018 -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biotechnology company developing an entirely new class of allogeneic cellular therapies, today.

  • Qatar Fund Building Venture Capital Unit for U.S. Startups
    Bloomberglast month

    Qatar Fund Building Venture Capital Unit for U.S. Startups

    The Qatar Investment Authority, created to handle the windfall from the country’s gas and oil exports, has invested in companies including Foursquare Labs Inc., biotech firm Rubius Therapeutics Inc., Homology Medicines Inc., Thoughtspot Inc. and Grail Inc., said the people, asking not to be identified because the deals are private.

  • Cambridge's Moderna sets record with $604M IPO
    American City Business Journalslast month

    Cambridge's Moderna sets record with $604M IPO

    The Cambridge biotech shattered records on Thursday night when it announced it had raised more than $604 million in an IPO, the largest ever in the sector.

  • GlobeNewswire2 months ago

    Rubius Therapeutics to Participate in Jefferies London Healthcare Conference

    CAMBRIDGE, Mass., Nov. 06, 2018 -- Rubius Therapeutics, Inc. (Nasdaq:RUBY),  a biotechnology company developing an entirely new class of allogeneic cellular therapies,.

  • GlobeNewswire2 months ago

    Rubius Therapeutics to Announce Third Quarter 2018 Financial Results

    CAMBRIDGE, Mass., Nov. 05, 2018 -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company developing an entirely new class of allogeneic cellular therapies, plans to.

  • ACCESSWIRE4 months ago

    Biotech Market is Rolling and These Companies Need to Be on Your Radar

    HENDERSON, NV / ACCESSWIRE / September 24, 2018 / Now that the biotechnology sector is well on its way to bouncing back after bottoming in May 2018, some investors may feel like they missed out. Don't ...

  • Rubius (RUBY) in Focus: Stock Moves 8.7% Higher
    Zacks4 months ago

    Rubius (RUBY) in Focus: Stock Moves 8.7% Higher

    Rubius (RUBY) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

  • Investor's Business Daily5 months ago

    How This Biotech IPO Is Facing Off Vs. BioMarin In Metabolic Disease

    Rubius Therapeutics could rival BioMarin Pharmaceutical in treating a metabolic disorder but, first, the duo will face a dark horse candidate in the form of Synlogic.